Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000

Pantuck Allan J, van Ophoven Arndt, Gitlitz Barbara J, Tso Cho-Lea, Acres Bruce, Squiban Patrick, Ross Michael E, Belldegrun Arie S, Figlin Robert A

Abstract excerpt

MUC-1 is overexpressed on many tumor cells. In addition, aberrant glycosylation of MUC-1 on human tumors leads to exposure of cryptic peptide epitopes that play a role in tumor immunity. As such, it has been identified as a potential target for immunotherapy. The purpose of this phase 1 clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to CD4 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8 Antigens

Share to Cell Separation

Share to Interleukin-2

Share to Mucin-1

Share to Th1 Cells

Share to Vaccinia virus

Source

Identifiers

PMID: 15076142
DOI: 10.1097/00002371-200405000-00009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15076142-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.PMID 15076142Read ↗

Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2Semantic proximity Read ↗

The Novel Oncolytic Herpes Simplex Virus Type-1 (HSV-1) Vaccine Strain VC2 Constitutively Expressing GM-CSF Causes Increased Intratumoral T Cell Infiltration and Inhibition of Tumor Metastasis in the 4T1/Balb/c Mouse Model of Stage Four Breast CancerSemantic proximity Read ↗

Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC.Semantic proximity Read ↗

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.Semantic proximity Read ↗

Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trialSemantic proximity Read ↗

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.Semantic proximity Read ↗

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.Semantic proximity Read ↗

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.Semantic proximity Read ↗

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4<sup>+</sup> T‐cell‐independent CD8<sup>+</sup> T‐cell‐mediated tumor controlSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.